-
The Future Of Nano Technology
Categories
- Ai
- Alan Watts
- Anatomy
- Andropause
- Anti-Aging Medicine
- Arthritis
- Artificial General Intelligence
- Artificial Intelligence
- Artificial Super Intelligence
- Ataxia
- Autism
- Biochemistry
- BioEngineering
- Biotechnology
- Bitcoin
- Chemistry
- Cryonics
- Cryptocurrency
- David Sinclair
- Dementia
- Diet Science
- Diseases
- Eczema
- Elon Musk
- Futurism
- Gene Medicine
- Gene Therapy
- Gene therapy
- Genetic Medicine
- Genetic Therapy
- Global News Feed
- Healthy Lifestyle
- Healthy Living
- HGH Physicians
- Hormone Optimization
- Hormone Replacement Therapy
- Hormone Replacement Treatment
- Human Genetic Engineering
- Human Immortality
- Human Longevity
- Human Reproduction
- Hypogonadism
- Hypopituitarism
- Hypothyroidism
- Immortality
- Immortality Medicine
- Inflammation
- Injectable Growth Hormone
- Integrative Medicine
- Life Skills
- Longevity
- Longevity Medicine
- Low T
- Machine Learning
- Mars Colony
- Medical School
- Menopause
- multiple-sclerosis
- Nano Medicine
- Nanomedicine
- Nanotechnology
- Neurology
- Parkinson's disease
- Pharmacogenomics
- Protein Folding
- Psoriasis
- Quantum Computing
- Regenerative Medicine
- Resveratrol
- Sermorelin Physicians
- Singularity
- Spacex
- Stem Cell Therapy
- Stem Cells
- Stemcell Therapy
- Testosterone
- Testosterone Physicians
- Transhuman
- Transhumanism
- Transhumanist
- Uncategorized
- Veganism
- Vegetarianism
- Vitamin Research
- Wellness
-
Recent Posts
- Googles Astra is its first AI-for-everything agent – MIT Technology Review
- Generative AI Is Totally Shameless. I Want to Be It – WIRED
- Verizon Expects to Double Network Thanks to AI Demand – PYMNTS.com
- Google’s new LearnLM AI model focuses on education – The Verge
- Google unveils Project Astra chatbot tech and brings ‘AI overview’ to search for all U.S. users – Fortune
Archives
Popular Key Word Searches
- centraltph
- bicarbonate and growth immunity ray peat
- vrcc neurology
- bibliotecapleyades/amrita-longevity-immortality
- cbr xmen anatomy
- Medical genetics wikipedia
- immortality medicine
- GrabPay
- Grab Pay Philippines
- GrabPay Vietnam
- GrabPay Philippines
- dr weil psoriasis
- what does recovered mean covid-19
- tony pantalleresco
- tony pantalleresco herbalist book
- herbsplusbeadworks
- herbsplusbeadworks website
- hailie vanderven
- princeton longevity center scam
- aetna genetic testing policy
- anatomy of hell
- biggie
- longevity claims
- augmentinforce tony pantalleresco
- tony pantalleresco website
Search Immortality Topics: |
Category Archives: Global News Feed
Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity
Bagsværd, Denmark, 5 November 2021 – Results from the STEP 5 phase 3b trial, presented today at the ObesityWeek® 2021 interactive congress, showed that adults treated with Wegovy™ (semaglutide 2.4 mg injection) achieved significant and sustained weight loss over the two-year study period. The STEP 5 trial investigated Wegovy™ vs. placebo, both used with a reduced calorie meal plan and increased physical activity for the treatment of obesity (BMI ?30 kg/m2) or overweight (BMI ?27 kg/ m2) in 304 adults with at least one weight-related comorbidity for 104 weeks (two years).1
Read more:
Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity
Posted in Global News Feed
Comments Off on Wegovy™ demonstrated significant and sustained weight loss in two-year study in adults with obesity
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study Next-Generation CDK2/9 Inhibitor Fadraciclib to Be Evaluated as a Single Agent and in Combinations in Streamlined, Registration-Directed Study
Originally posted here:
Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
Posted in Global News Feed
Comments Off on Cyclacel Announces Dosing of First Patient in Phase 1/2 Study of Oral Fadraciclib in Patients With Leukemias or Myelodysplastic Syndromes
I-MED Pharma Set to Launch Its Innovative Dry Eye Product Portfolio in the U.S.A.
MONTREAL, Nov. 05, 2021 (GLOBE NEWSWIRE) -- I-MED Pharma USA is bringing the world’s most innovative dry eye product portfolio to the U.S. market. Their uniquely formulated line of ocular surface disorder products gives dry eye patients the long-lasting relief they have been searching for. I-MED Pharma USA will sell directly to eye care professionals throughout the United States, offering a broad range product portfolio which includes I-DROP® artificial tears, I-LID ’N LASH® ocular hygiene cleansers, I-DEFENCE® night-time dry eye ointment, I-VU® OMEGA-3 nutritional supplements, I-RELIEF™ therapeutic mask, and the E>Eye IRPL® device specifically designed to treat evaporative dry eye due to meibomian gland dysfunction.
Go here to see the original:
I-MED Pharma Set to Launch Its Innovative Dry Eye Product Portfolio in the U.S.A.
Posted in Global News Feed
Comments Off on I-MED Pharma Set to Launch Its Innovative Dry Eye Product Portfolio in the U.S.A.
PAOG Announces Plans To Add New Pharmaceutical Product Developments
Sandusky, OH, Nov. 05, 2021 (GLOBE NEWSWIRE) -- PAO Group, Inc. (OTC Pink: PAOG) today announced plans to add multiple new pharmaceutical products to its development pipeline in addition to its ongoing development of its RespRx CBD pharmaceutical for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Link:
PAOG Announces Plans To Add New Pharmaceutical Product Developments
Posted in Global News Feed
Comments Off on PAOG Announces Plans To Add New Pharmaceutical Product Developments
MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market
BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (Nasdaq:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, announces that its shares have commenced trading today on the Nasdaq Capital Market under the ticker symbol “MYNZ”.
Read more:
MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market
Posted in Global News Feed
Comments Off on MYNZ Shares Have Commenced Trading on the Nasdaq Capital Market
Bavarian Nordic to Host Third Quarter 2021 Results Conference Call
COPENHAGEN, Denmark – November 5, 2021 - Bavarian Nordic A/S (OMX: BAVA) will announce its 2021 third quarter results on Friday, November 12, 2021.
Continue reading here:
Bavarian Nordic to Host Third Quarter 2021 Results Conference Call
Posted in Global News Feed
Comments Off on Bavarian Nordic to Host Third Quarter 2021 Results Conference Call